Submit a comment
Citation Information: J Clin Invest. 1981;67(6):1703-1711. https://doi.org/10.1172/JCI110208.
Selectivity of Dobutamine for Adrenergic Receptor Subtypes: IN VITRO ANALYSIS BY RADIOLIGAND BINDING
Abstract
The cardiovascular responses elicited by dobutamine are distinctly different from those produced by other adrenergic or dopaminergic agonists. To test the hypothesis that dobutamine could have differential affinities for adrenergic receptor subtypes, and that such subtype selectivity could be related to its relatively unique pharmacologic properties, we assessed the ability of dobutamine to displace adrenergic radioligands from membrane receptors in a number of tissues of previously characterized adrenergic receptor subtype. For beta adrenergic receptors identified by (−) [3H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the β1 subtype (KD = 2.5 μM in rat heart and 2.6 μM in turkey erythrocyte) than for the β2 subtype (KD = 14.8 μM in frog heart and 25.4 μM in rat lung) (P < 0.001). For alpha adrenergic receptors, dobutamine had markedly greater affinity for the α1-subtype identified by [3H]prazosin (KD = 0.09 μM in rat heart and 0.14 μM in rabbit uterus) than for the α2-subtype identified by [3H]dihydroergocryptine (DHE) (KD = 9.3 μM in human platelet) or by [3H]yohimbine (KD = 5.7 μM in rabbit uterus) (P < 0.001).
Authors
R. Sanders Williams, Timothy Bishop
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)